メインコンテンツに移動
翻訳中 — お使いの言語版を準備している間、このコンテンツは英語で表示されています。
ディスカッションに戻る

Trends in Buprenorphine and Methadone Dispensing Among Medicare Advantage and Commercial Enrollees, 2019-2024

Healthcare
United States
August 27, 2026に開始

This study examined national trends in methadone and buprenorphine dispensing among Medicare Advantage and commercial enrollees with opioid use disorder from 2019 to 2024, characterizing differences by insurance type, age, and dual eligibility

ソース記事

主張を追加 分析 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
10 投票すべき主張 • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (10+ recommended) 10/10
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 投稿者： admin • Aug 27, 2026
Access to both buprenorphine and methadone should be expanded for all enrollees to address opioid use disorder effectively.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results
CLAIM 投稿者： admin • Aug 27, 2026
The age demographic of enrollees significantly influences the type of opioid treatment they receive.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results
CLAIM 投稿者： admin • Aug 27, 2026
Buprenorphine dispensing among Medicare Advantage enrollees has significantly increased from 2019 to 2024.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results
CLAIM 投稿者： admin • Aug 27, 2026
Dual-eligible individuals have the highest rates of buprenorphine dispensing compared to other groups.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results
CLAIM 投稿者： admin • Aug 27, 2026
Insurance type should not dictate the quality of care for individuals with opioid use disorder.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results
CLAIM 投稿者： admin • Aug 27, 2026
Methadone dispensing has declined sharply among commercial enrollees during the same period.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results
CLAIM 投稿者： admin • Aug 27, 2026
Regulatory barriers continue to hinder equitable access to methadone for those in need.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results
CLAIM 投稿者： admin • Aug 27, 2026
Both Medicare Advantage and commercial plans should collaborate to improve treatment accessibility for opioid use disorder.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results
CLAIM 投稿者： admin • Aug 27, 2026
The rise in buprenorphine use indicates a shift towards more effective treatment options for opioid use disorder.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results
CLAIM 投稿者： admin • Aug 27, 2026
Commercial enrollees experience barriers to accessing methadone treatment due to insurance restrictions.

翻訳準備中

Vote options for this statement: agree, disagree, or unsure
💬 ディスカッションを見る
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us